US 11,771,682 B2
AR+ breast cancer treatment methods
Gary Hattersley, Stow, MA (US); Jamal Saeh, Belmont, MA (US); Ziyang Yu, Wellesley, MA (US); Chris Miller, San Mateo, CA (US); and Teeru Bihani, Boston, MA (US)
Assigned to Ellipses Pharma Ltd., London (GB)
Filed by ELLIPSES PHARMA LTD., London (GB)
Filed on Nov. 26, 2019, as Appl. No. 16/696,110.
Application 16/696,110 is a continuation of application No. 15/628,559, filed on Jun. 20, 2017, abandoned.
Claims priority of provisional application 62/461,546, filed on Feb. 21, 2017.
Claims priority of provisional application 62/377,497, filed on Aug. 19, 2016.
Claims priority of provisional application 62/353,350, filed on Jun. 22, 2016.
Prior Publication US 2020/0171008 A1, Jun. 4, 2020
Int. Cl. A01N 43/00 (2006.01); A01N 43/46 (2006.01); A61K 31/55 (2006.01); A61K 31/4245 (2006.01); A61K 31/519 (2006.01); A61K 31/436 (2006.01); A61K 31/138 (2006.01)
CPC A61K 31/4245 (2013.01) [A61K 31/138 (2013.01); A61K 31/436 (2013.01); A61K 31/519 (2013.01)] 13 Claims
 
1. A method of treating AR+/ER+breast cancer in a subject in need thereof, the method comprising administering to the subject a compound which is RAD140 (Compound III)

OG Complex Work Unit Chemistry
a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.